Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP for reducing blood loss during laparoscopic hepatectomy in hepatic cancer
ChiCTR2300072355Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nesiritide in liver cancer (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Intraoperative blood loss. Planned start May 2023; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
liver cancer
Beyond the preview
Go deeper on ChiCTR2300072355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072355.